Modulation of transthyretin expression

Abstract

Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.

1 .- 18 . (canceled) 
     
     
         19 . A formulation comprising a liposome and a modulator of transthyretin expression, wherein the liposome comprises a cationic lipid. 
     
     
         20 . The formulation of  claim 19 , wherein the modulator of transthyretin expression is an antisense compound, an antisense oligonucleotide, or a ribozyme capable of hybridizing to at least a portion of SEQ ID NO: 4. 
     
     
         21 . The formulation of  claim 20 , wherein the antisense compound is single-stranded. 
     
     
         22 . The formulation of  claim 20 , wherein the antisense compound comprises a modified oligonucleotide 20 to 25 nucleobases in length having at least one modified sugar moiety. 
     
     
         23 . The formulation of  claim 22 , wherein the modified oligonucleotide is at least 95% complementary to SEQ ID NO: 4. 
     
     
         24 . The formulation of  claim 19 , wherein the modulator is complexed to the cationic liposome. 
     
     
         25 . The formulation of  claim 19 , wherein the cationic lipid comprises dioleoyltetramethylaminopropyl or dioleoylphosphatidyl ethanolamine. 
     
     
         26 . The formulation of  claim 19 , wherein the modulator is encapsulated within the liposome. 
     
     
         27 . The formulation of  claim 20 , wherein the modulator is encapsulated within the liposome. 
     
     
         28 . The formulation of  claim 21 , wherein the modulator is encapsulated within the liposome. 
     
     
         29 . The formulation of  claim 22 , wherein the modulator is encapsulated within the liposome. 
     
     
         30 . The formulation of  claim 23 , wherein the modulator is encapsulated within the liposome. 
     
     
         31 . The formulation of  claim 25 , wherein the modulator is encapsulated within the liposome.